Company intelligence / Profile preview

Amzell B.V.

Hoofddorp, Netherlands

Ownership: Private
Development stage: Other

Overview

AMZ001 (osteoarthritis) completed Phase 2 clinical trial with results presented at OARSI World Congress 2020. AMZ002 (infantile epileptic disease) has entered Phase 3 clinical trials in the U.S. as of November 2021. AMZ004 (nausea and vomiting in pregnancy) was planned for Phase 1 clinical study in 2021.

Therapeutic areas: RheumatologyWomen's HealthNeurology
Modalities: Small moleculessynthetic polypeptidestransdermal formulations
Industry: Biotech

Drug pipeline

3 assets

diclofenac (AMZ001 formulation)

2 more assets in the full pipeline.

Request access →

Partnerships

Amring Pharmaceuticals Inc.Ferring Pharmaceuticals

Beyond the preview

Go deeper on Amzell B.V..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amzell B.V..

Explore the full profile